U.S. Therapeutic Plasma Exchange Market by Indication, Procedures & Patients - Forecasts to 2021

  • ID: 3785830
  • Report
  • Region: United States
  • 91 Pages
  • Markets and Markets
1 of 4
The U.S. Therapeutic Plasma Exchange (TPE) Market by Indication is Estimated to Reach USD 260.0 Million by 2021, Growing at A CAGR Of 11% To 12% During the Forecast Period 2016 to 2021

FEATURED COMPANIES

  • B. Braun Melsungen AG
  • Baxter International Inc
  • Fresenius Se & Co. KGAA
  • Haemonetics Corporation
  • Hemacare Corporation
  • Terumo BCT, Inc.
  • MORE
U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences of blood disorders and chronic diseases; rapid increase in the aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving the therapeutic plasma exchange market in the U.S. In this report, the market is segmented by indication, number of patients, and total number of TPE procedures performed by indication.

Therapeutic plasma exchange removes plasma components from blood. A blood cell separator extracts the patient’s plasma and returns red blood cells (RBCs) and platelets in plasma or a plasma-replacing fluid; for this purpose, 5% albumin is preferred to fresh frozen plasma (except for patients with thrombotic thrombocytopenic purpura) because it causes fewer reactions and transmits no infections. Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components. Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture syndrome, and Wegener’s Granulomatosis. This trend is expected to continue in the coming years as well.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the therapeutic plasma exchange market. The report analyzes the therapeutic plasma exchange market by indication, total number of TPE procedures performed, and number of patients treated with TPE in the U.S.

- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the therapeutic plasma exchange market

- Market Diversification: Exhaustive information about new products, major product segments and indications, recent developments, and investments in the therapeutic plasma exchange market

Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution networks, manufacturing capabilities, and product portfolio and pricing analyses of the leading players in the therapeutic plasma exchange market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • B. Braun Melsungen AG
  • Baxter International Inc
  • Fresenius Se & Co. KGAA
  • Haemonetics Corporation
  • Hemacare Corporation
  • Terumo BCT, Inc.
  • MORE
1 Introduction
1.1 Objectives and Scope
1.2 Research Methodology
1.3 Market Estimation Methodology
1.4 Primary Research Methodology
1.5 Primary Respondent Profile

2 Key Insights

3 Therapeutic Plasma Exchnage Market, By Indication
3.1 Guillain-Barré Syndrome (GBS)
3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.3 Myasthenia Gravis (MG)
3.4 Multiple Sclerosis (MS)
3.5 Neuromyelitis Optica (NMO)
3.6 Thrombotic Thrombocytopenic Purpura (TTP)
3.7 Cryoglobulinemia
3.8 Multiple Myeloma (MM)
3.9 Waldenstrom Macroglobulinemia (WM)
3.10 Hemolytic Uremic Syndrome (HUS)
3.11 Anti-GBM Disease (Goodpasture’s Syndrome)
3.12 Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
3.13 Post-Renal Transplant Rejection
3.14 Familial Hypercholesterolemia (Homozygous)
3.15 Anca-Associated Vasculitis

4 Appendix
4.4.1 Company Profiles
4.4.1.1 Fresenius Se & Co. KGAA
4.4.1.2 B. Braun Melsungen AG
4.4.1.3 Baxter International Inc
4.4.1.4 Asahi Kasei Medical Co., Ltd.
4.4.1.5 Terumo BCT, Inc.
4.4.1.6 Haemonetics Corporation
4.4.1.7 Kawasumi Laboratories, Inc.
4.4.1.8 Hemacare Corporation
4.5 Knowledge Store: Subscription Portal

List of Tables (55 Tables)

Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014-2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market- Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Table 20 Treatment Guidelines & Protocols : Thrombotic Thrombocytopenic Purpura (TTP)
Table 21 Epidemiology : Thrombotic Thrombocytopenic Purpura (TTP)
Table 22 U.S. Disease Statistics: Cryoglobulinemia
Table 23 Treatment Guidelines & Protocols : Cryoglobulinemia
Table 24 Epidemiology : Cryoglobulinemia
Table 25 U.S. Disease Statistics: Multiple Myeloma (MM)
Table 26 Treatment Guidelines & Protocols : Multiple Myeloma (MM)
Table 27 Epidemiology : Multiple Myeloma (MM)
Table 28 U.S. Disease Statistics: Waldenstrom Macroglobulinemia (WM)
Table 29 Treatment Guidelines & Protocols : Waldenstrom Macroglobulinemia (WM)
Table 30 Epidemiology : Waldenstrom Macroglobulinemia (WM)
Table 31 U.S. Disease Statistics: Hemolytic Uremic Syndrome (HUS)
Table 32 Treatment Guidelines & Protocols : Hemolytic Uremic Syndrome (HUS)
Table 33 Epidemiology : Hemolytic Uremic Syndrome (HUS)
Table 34 U.S. Disease Statistics: Anti-GBM Disease (Goodpasture’s Syndrome)
Table 35 Treatment Guidelines & Protocols : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 36 Epidemiology : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 37 U.S. Disease Statistics: Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis
Table 38 Treatment Guidelines & Protocols : Wegener’s Granulomatosis
Table 39 Epidemiology : Wegener’s Granulomatosis
Table 40 U.S. Disease Statistics: Post-Renal Transplant Rejection
Table 41 Treatment Guidelines & Protocols : Post-Renal Transplant Rejection
Table 42 Epidemiology : Post-Renal Transplant Rejection
Table 43 U.S. Disease Statistics: Familial Hypercholesterolemia (Homozygous)
Table 44 Treatment Guidelines & Protocols : Familial Hypercholesterolemia (Homozygous)
Table 45 Epidemiology : Familial Hypercholesterolemia (Homozygous)
Table 46 U.S. Disease Statistics: Anca-Associated Vasculitis
Table 47 Epidemiology Data
Table 48 Details of Primary Respondents (1/8)
Table 49 Details of Primary Respondents (2/8)
Table 50 Details of Primary Respondents (3/8)
Table 51 Details of Primary Respondents (4/8)
Table 52 Details of Primary Respondents (5/8)
Table 53 Details of Primary Respondents (6/8)
Table 54 Details of Primary Respondents (7/8)
Table 55 Details of Primary Respondents (8/8)

List of Figures

Figure 1 Research Methodology
Figure 2 Market Estimation Methodology
Figure 3 Primary Research Methodology
Figure 4 Respondent Profile, By Organization
Figure 5 Respondent Profile, By Designation
Figure 6 Industry Speaks (1/3)
Figure 7 Industry Speaks (2/3)
Figure 8 Industry Speaks (3/3)
Figure 9 Knowledge Store Snapshot
Figure 10 Knowledge Store: Healthcare Industry Snapshot
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Asahi Kasei Medical Co., Ltd.
- B. Braun Melsungen AG
- Baxter International Inc
- Fresenius Se & Co. KGAA
- Haemonetics Corporation
- Hemacare Corporation
- Kawasumi Laboratories, Inc.
- Knowledge Store: Subscription Portal
- Terumo BCT, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll